Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained / How Novo Nordisk's Board Built a Weight-Loss Empire
Transcript
- Lucas: If these conversations have moved your work forward in some small way, I'll say this up front — the reason this show stays ad-free is listener support. It's a small thing, but buy me a coffee dot com slash fexingo goes directly to keeping the lights on here. Luna: Yeah, and we mean it. We don't do sponsors, we don't do mid-rolls. So if you get value, that link is the whole engine. Lucas: Exactly. Now — Novo Nordisk. A Danish pharmaceutical company that, a decade ago, was best known for insulin. Today its market cap sits north of six hundred billion dollars. That's larger than the entire economy of Denmark. Luna: I still have to pause on that number. A single company worth more than its home country's GDP. How did the board steer that? Lucas: Well, it starts with a bet they placed around 2015. The board approved a massive expansion of manufacturing capacity for semaglutide — the active ingredient in Ozempic and later Wegovy — years before the FDA approved it for weight loss. Luna: So they were building factories for a drug that wasn't even approved for the indication that would make it blockbuster. That's a board-level conviction call. Lucas: Exactly. At the time, semaglutide was approved for type 2 diabetes under the brand name Ozempic. The obesity indication was still in clinical trials. But the board looked at the data — not just efficacy, but the sheer size of the addressable market. Globally, over a billion people are classified as obese. Luna: And they knew that if it worked, manufacturing would be the bottleneck. So they approved a multi billion dollar capital expenditure program to build out production in Denmark, the US, and later China. Lucas: Right. That decision is the kind of thing that separates great boards from good ones. Most boards would say, 'Let's wait for approval, then scale.' Novo's board said, 'The science is compelling enough. We build now.' Luna: What was the board composition like at that time? Was it insiders or independent directors pushing that? Lucas: The board then was chaired by Göran Ando, a physician and former executive at AstraZeneca. He had deep pharma expertise. And the CEO was Lars Fruergaard Jørgensen, who had spent his whole career at Novo. So you had a board that understood the science and the manufacturing complexity. Luna: That combination — scientific literacy on the board and operational experience in the C-suite — is rare. Most pharma boards have a lot of financial chops but maybe one or two with R&D backgrounds. Lucas: And Novo's board structure actually enforces that. The company has a foundation ownership model — the Novo Nordisk Foundation owns about 77 percent of the voting shares. That foundation's board includes scientists, doctors, and public health experts. Luna: So the board is incentivized to think in decades, not quarters. That's a huge advantage when you're making a bet that won't pay off for five or six years. Lucas: Exactly. And it paid off spectacularly. Wegovy was approved for chronic weight management in the US in June 2021. Demand was so high that Novo couldn't keep up. They had to limit starter doses to preserve supply for existing patients. Luna: And that's where the board's earlier capacity bet really showed its wisdom. If they had waited, they'd be scrambling for years. Instead, they had new plants coming online just as demand exploded. Lucas: But it wasn't smooth. In 2023, the board had to approve another multi billion dollar investment — this time to acquire a contract manufacturer from its parent Catalent for eleven billion dollars. That was a defensive move to secure more production. Luna: Eleven billion for a factory network. That's a bold M&A decision for a board that normally prefers organic growth. Lucas: Right. And they faced criticism for the price tag. But the board's rationale was: we control our own destiny. They didn't want to be dependent on third-party manufacturers who might prioritize other clients. Luna: Interesting. So the board is not just approving big numbers — they're making strategic choices about vertical integration in a supply-constrained world. Lucas: Exactly. And they're also managing competitive threats. Eli Lilly has its own GLP-1 drug, tirzepatide, sold as Mounjaro for diabetes and now Zepbound for weight loss. That's a formidable competitor with deep pockets. Luna: How is the board positioning Novo to compete? Because Lilly is also building massive plants. Lucas: The board's strategy has been to double down on oral formulations. They have an oral semaglutide, Rybelsus, already on the market, but it's not as potent as the injectable. They're investing in next-generation oral GLP-1 drugs that could be more convenient. Luna: So the board is thinking about product differentiation beyond just manufacturing scale. Pills vs. injections. Lucas: And they're also looking at combination therapies. Novo is developing a drug that combines semaglutide with another hormone called amycretin, which could offer even greater weight loss. The board approved early-stage trials in 2024. Luna: That's classic portfolio thinking. Don't put all your bets on one molecule, even if it's a blockbuster. Lucas: Yeah. And the board also has to manage the social and political dimensions. Weight-loss drugs have become a cultural phenomenon, but also a target for pricing criticism. Novo charges about thirteen hundred dollars a month for Wegovy before insurance. Luna: That drew congressional scrutiny in the US. How did the board handle that? Lucas: They leaned into value-based pricing. Their argument: obesity is a chronic disease, and treating it reduces downstream costs for diabetes, heart disease, and other conditions. The board backed a study showing that Wegovy reduced cardiovascular events by twenty percent. Luna: So they armed themselves with clinical data to defend the price. That's a board saying: we will not compete on price, we will compete on outcomes. Lucas: Exactly. And they've also had to manage the regulatory and reputation risks around supply shortages. In 2023, some compounding pharmacies started making copycat versions. The board took legal action to protect their patents. Luna: Which speaks to the board's role in IP strategy. They're not just approving R&D budgets; they're overseeing patent litigation and regulatory filings. Lucas: And the foundation ownership structure gives them a long leash for those fights. They can afford to litigate for years because they're not worried about quarterly earnings pressure. Luna: That's the advantage of having patient capital baked into your governance. Most boards can't say, 'We'll spend three hundred million on a lawsuit and not worry about EPS dilution.' Lucas: Right. Novo's board also has to plan for the day when the GLP-1 patent cliff arrives — semaglutide patents start expiring in the early 2030s. They're already investing in next-generation biologics and gene therapies. Luna: So the board is effectively building the pipeline that will replace Wegovy and Ozempic. That's a very long-horizon governance approach. Lucas: It is. And it raises a question for our listeners: how does your board's timeframe compare? Are you making decisions for the next quarter or the next decade?